Bluejay Diagnostics, Inc. (BJDX) - Company Revenue

Intense competition in the rapid test segment is putting pressure on Bluejay Diagnostics (BJDX) gross sales revenue, which remains at 0.00. The lack of operating income and reliance on equity issuance confirm financial instability. Simultaneously, Bluejay Diagnostics is implementing eco-friendly packaging to reduce energy costs. This chart illustrates current cash flow trends, helping to assess capital sustainability.

BJDX - Bluejay Company Sales over the range 07/04/2022 - 11/13/2026

Analytical breakdowns for Bluejay Diagnostics

- market value and analyst target forecast:

Market Chart Bluejay Diagnostics Corp|BJDX - Analyst Consensus Forecast

- market capitalization indicators:

Market Value Bluejay Diagnostics, Inc.|BJDX - Total Company Value

- book capitalization information:

Net Assets per Single Share Bluejay Diagnostics|BJDX - Company Net Assets|Market Capitalization to Book Value Ratio bluejaydx.com|BJDX - Company Total Assets

- company liabilities and liquidity data:

- earnings and market ratios statistics:

BJDX - Net Profit|Net Profit Forecast Bluejay Diagnostics|BJDX - P/E Multiple|Market Cap to Projected Earnings bluejaydx.com|BJDX - PEG Multiple|EV/EBITDA Multiple Bluejay Diagnostics, Inc.|BJDX - Operating profit EBITDA|Net earnings per share for the trailing year Bluejay Diagnostics|BJDX - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last 12 months bluejaydx.com|BJDX - Earnings per share growth in current year|Expected net earnings per share growth next year Bluejay Diagnostics

- issuer revenue and sales details:

BJDX - Company Revenue|Company Future Sales Bluejay Diagnostics Corp|BJDX - Market Cap to Revenue|Price to Expected Revenue Ratio Bluejay Diagnostics, Inc.

Summary company analysis:BJDX, Bluejay Diagnostics Corp

This indicator is based on the aggregation of daily cash inflows from product sales, which allows for the neutralization of random market noise and the identification of true business activity cycles. Analyzing the sales velocity of Bluejay Diagnostics (BJDX) helps assess the company's commercial resilience amid fierce competition and risks associated with FDA approval of sepsis tests, thereby determining the entry point into the asset.

Competing companies